Portfolio data

Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP

• Late-stage clinical companies
• Beacon Therapeutics

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

• Operating News
• Late-stage clinical companies
• Autolus Therapeutics

Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial

• Clinical companies
• Spur Therapeutics

Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024

• Pre-clinical companies
• Resolution Therapeutics

Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients

• Clinical companies
• Quell Therapeutics

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting